We are focused on developing and commercializing drugs that treat orphan disease populations.
Our lead product candidate, ARIKAYCE, is being developed for patients with severe lung infections.
ARIKAYCE is a proprietary inhaled liposomal formulation of the antibiotic amikacin, currently administered intravenously for a range of infections
The product is delivered through a specialized nebulizer engineered to deliver amikacin directly to the site of serious lung infections
ARIKAYCE is designed for once daily administration
We have multiple near‐term commercial opportunities in orphan lung diseases.
In 2014, Insmed filed a Marketing Authorization Application (MAA) with the EMA for ARIKAYCE for the treatment of NTM lung infections as well as Pseudomonas aeruginosa lung infections in cystic fibrosis patients.
Insmed is proceeding with a phase 3 study in patients with NTM lung infection. We anticipate having preliminary top-line clinical results from the confirmatory phase 3 study in 2016.
We have a solid and broad IP portfolio.
More than a decade of investment in research and development
Potential coverage into 2029
We are well-capitalized and are building out our infrastructure.
$159.2 million in cash (as of December 31, 2014)
Jul 28, 2015
Insmed to Host Second Quarter 2015 Financial Results Conference Call on Thursday, August 6, 2015
Jun 17, 2015
Insmed to Participate at the JMP Securities Life Sciences Conference
Aug 6, 2015
Insmed Second Quarter 2015 Financial Results
Listen to webcast
Jun 24, 2015
Insmed to participate at the 2015 JMP Securities Life Sciences Conference
Listen to webcast
View the latest Insmed Investor Presentation here.
Key Clinical Publications
Insmed actively publishes and presents clinical data for its product candidates.
Want to stay up to date on our news, events, and filings?
Set up your email alerts. Learn More
Investor & Media Contacts
Insmed Investor Relations
Phone: (908) 947-4326